In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

The BAG3 gene mutations in Polish patients with dilated cardiomyopathy

Session Poster session 1

Speaker Maria Franaszczyk

Congress : ESC Congress 2014

  • Topic : basic science
  • Sub-topic : Basic Science
  • Session type : Poster Session
  • FP Number : P612

Authors : M Franaszczyk (Warsaw,PL), ZT Bilinska (Warsaw,PL), M Sobieszczanska-Malek (Warsaw,PL), E Michalak (Warsaw,PL), J Sleszycka (Warsaw,PL), A Sioma (Warsaw,PL), G Religa (Warsaw,PL), J Grzybowski (Warsaw,PL), T Zielinski (Warsaw,PL), R Ploski (Warsaw,PL)

Authors:
M. Franaszczyk1 , Z.T. Bilinska2 , M. Sobieszczanska-Malek3 , E. Michalak2 , J. Sleszycka4 , A. Sioma2 , G. Religa5 , J. Grzybowski4 , T. Zielinski3 , R. Ploski6 , 1National Institute of Cardiology, Laboratory of Molecular Biology - Warsaw - Poland , 2National Institute of Cardiology, Unit for Screening Studies in Inherited Cardiovascular Diseases - Warsaw - Poland , 3National Institute of Cardiology, Department of Heart Failure and Transplantology - Warsaw - Poland , 4National Institute of Cardiology, Department of Cardiomyopathies - Warsaw - Poland , 5National Institute of Cardiology, Department of Cardiac Surgery - Warsaw - Poland , 6Medical University of Warsaw, Department of Medical Genetics, Centre of Biostructure - Warsaw - Poland ,

Citation:
European Heart Journal ( 2014 ) 35 ( Abstract Supplement ), 107

Purpose: Dilated cardiomyopathy (DCM) is a major cause of chronic heart failure and the most common indication for cardiac transplantation. BAG3 gene mutations have been recently implicated as a novel cause of dilated cardiomyopathy (DCM). Our aim was to evaluate the prevalence of BAG3 mutations in Polish patients with DCM.

Methods: We studied 105 unrelated probands by direct sequencing of BAG3 exons and splice sites. Large deletions/insertions were screened for by real time polymerase chain reaction (RT-PCR).

Results: We found 6 different mutations in 7 families with familial DCM: the known p.Glu455Lys mutation (2 families) and 5 novel mutations: p.Gln353ArgfsX10 (c.1055delC), p.Gly379AlafsX45 (c.1135delG), p.Tyr451X (c.1353C>A), p.Glu456AspfsX3 (c.1368delG) and a large deletion of 17,990bp removing BAG3 exons 3-4. The Gln353ArgfsX10, Gly379AlafsX45, and the large deletion are likely to be pathogenic as they are predicted to remove a large C-terminal part of the protein, including the entire BAG domain. The Tyr451X and Glu456AspfsX3 are also likely to be pathogenic as they remove more than half of the BAG domain.

There were 31 BAG3 mutation carriers; mean age at the time of diagnosis/screening was 30.4±12.6 years, 20 (64.5%) were male. 10 subjects were asymptomatic (32.3%), 20 (64.5%) had heart failure symptoms; mean NYHA class was 2.5±1.1, 1 (3.2%) had palpitations. Of the 31 carriers 28 (90%) were in sinus rhythm, 2 were in atrial fibrillation (6.5%), 1 had junctional rhythm (3.2%). DCM was diagnosed in 20 patients (65%), 11 BAG3 carriers (35%) had normal cardiac function. Over mean 95.3±81.9 months of follow-up (median 95.3 months) there were 7 (22.6%) serious adverse events: 3 patients received heart transplant (9.7%), 3 died of heart failure (9.7%), 1 died suddenly (3.7%). Persistent LV dysfunction (LVEF<45%) was present in 9 (29%) patients, 4 had significant improvement in LV function on treatment 4 (12.9%), and 11 BAG3 carriers had persistent normal LV function (35.5%). Among members of screened families there were no cases of DCM without BAG3 mutation. Of interest, all BAG3 carriers with persistent normal LV function had BAG3 truncating mutations.

Conclusions: BAG3 mutations are relatively frequent cause of DCM (6.7%). We report five novel pathogenic BAG3 variants including a large deletion Our observations highlight the necessity for screening BAG3 in DCM patients for copy number variations (CNV) variants in addition to point mutations.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are